Lionel de Hemptinne

Chief Financial Officer

Member of the Group Executive Committee at Luxempart



Profile

Senior finance and investment executive with 15+ years of leadership and board experience across listed and private investment companies. Proven track record in corporate finance, governance, tax and legal structuring, and strategic development. Broad exposure to portfolio companies across multiple sectors and international environments.

Core Expertise

- Corporate finance / IFRS
- Financing & Capital structure
- M&A / Investment execution
- Listed company environment
- Governance
- Strategy

Languages

- French
- Dutch
- English

Education

- Executive Master in Finance
  Solvay Business School | 2009
- Master in Business Engineering, Cum Laude
  Louvain School of Management | 2003

Professional Experience (since 2010)

Luxempart SA (listed company) / 2022 - Present
Chief financial officer, member of the Group Executive Committee

- Oversees all corporate functions, including Finance, Tax, Legal, HR and Investor Relations.
- Member of the Group Executive Committee and Group Investment Committees.
- Serves on the boards of Foyer Group (Luxembourg) and iM Global Partners (France).

Droia Oncology Ventures / 2019 - 2022 Chief Financial Officer

- Led the Corporate and Structuring teams.
- Oversaw the financial, tax and legal structuring of the funds and portfolio companies.
- Developed strong exposure to the biotech and venture capital ecosystem.

Floridienne Group (listed company) / 2010 - 2019 Chief Finance & Investments Officer

- Led corporate functions across Finance, Tax, Legal, HR and Investor Relations.
- Contributed to the Group's buy-and-build strategy and portfolio development.
- Served as CEO of portfolio company Delka from 2010 to 2013.
- Held board mandates at Enzybel Group (Belgium), Kimflor (Turkey), SNAM (France) and Delka (Belgium).